Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Drivers of New Rozanolixizumab Treatment Cycles in Patients with Generalized Myasthenia Gravis in the Phase 3 MycarinG and Open-label Extension Studies

Author:Mahuwala, Zabeen K.   Grosskreutz, Julian   Habib, Ali A.   Mantegazza, Renato   Pascuzzi, Robert M.   Sacconi, Sabrina   Vissing, John   Vu, Tuan   Beau-Lejdstrom, Raphaelle   Greve, Bernhard   Grimson, Fiona   Tarancón, Thaïs   Bril, Vera   

Session Name:P10: Neuromuscular and Clinical Neurophysiology (EMG): Myasthenia Gravis 3  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P10.003  

Author Institution:Department of Neuromuscular Medicine, Epilepsy and Clinical Neurophysiology, University of Kentucky, Lexington, KY, USA, LEXINGTON, KY  Precision Neurology, Department of Neurology, University of Lübeck, Lübeck, Germany, Lübeck, Germany  MDA ALS and Neuromuscular Center, University of California, Irvine, Irvine, CA, USA, Orange, CA  Department of Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy, Milan, Italy  Neurology Department, Indiana University School of Medicine, Indiana University Health, Indianapolis, IN, USA, Indianapolis, IN  Université Côte d'Azur, Peripheral Nervous System & Muscle Department, Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice, Nice, France, Nice, France  Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark  Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA, Tampa, FL  UCB Pharma, Bulle, Switzerland, Bulle, Switzerland  UCB Pharma, Monheim, Germany, Monheim, Germany  UCB Pharma, Slough, UK, London, United Kingdom  UCB Pharma, Madrid, Spain, Madrid, Spain  University Health Network, Toronto, ON, Canada, Toronto, ON, Canada  

Combatting “Neurophobia”: A Proposed Preliminary Educational Model to Promote “Neurophilia”